NCI-MATCH: Promising signal for nivolumab beyond colorectal cancer

(ECOG-ACRIN Cancer Research Group) The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH, investigating the activity of nivolumab in tumors with DNA mismatch repair deficiencies. Eighteen different cancer types were studied, mostly rare and none colorectal, with DNA repair defects. The results showed a promising signal for nivolumab beyond colorectal cancer. The 36% response rate across a range of cancers compares well with a previous 31% response in colon cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news